OverviewSuggest Edit
Biogen is a biopharmaceutical company that discovers, develops and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases. It is primarily focused on developing medicines to treat multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. The company also manufactures and commercializes biosimilars of advanced biologics.
| Type | Public | |
| Founded | 1978 | |
| HQ | Cambridge, US | Map |
| Website | biogen.com | |
| Employee Ratings | More | |
| Culture score | B | More |
Recent NewsAll News
- Biogen Presents Positive Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020
- Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science
- NYT: Biogen event led to 'superspreading' of COVID-19 among employees and their contacts
- Thinking about trading options or stock in Biogen, Clorox, Centene, Netflix, or Walmart?
Key People/Management at Biogen
Michel Vounatsos
Chief Executive Officer and Director
Stelios Papadopoulos
Chairman of the Board
Susan Alexander
Executive Vice President, Chief Legal Officer and Secretary
Jeffrey Capello
Executive Vice President, Chief Financial Officer
Alphonse Galdes
Executive Vice President, Pharmaceutical Operations and Technology
Ginger Gregory
Executive Vice President, Chief Human Resource Officer
Biogen Office Locations
Biogen has offices in Cambridge, Morrisville, Waltham, Washington and in 35 other locations
Cambridge, US (HQ)
225 Binney St
Morrisville, US
5000 Davis Dr
Waltham, US
203 Crescent St #303
Washington, US
601 Pennsylvania Ave NW #720
Weston, US
133 Boston Post Rd
Vicente López, AR
7th Floor, Av. del Libertador 350
Biogen Financials and Metrics
Biogen Revenue
Biogen's revenue was reported to be $14.38 b in FY, 2019 which is a 6.9% increase from the previous period.
| USD | |
|---|---|
Revenue (Q1, 2020) | 3.5b |
Gross profit (Q1, 2020) | 3.1b |
Gross profit margin (Q1, 2020), % | 87.1% |
Net income (Q1, 2020) | 1.4b |
EBIT (Q1, 2020) | 1.8b |
Market capitalization (4-Jun-2020) | 48.9b |
Closing stock price (4-Jun-2020) | 299.6 |
Cash (31-Mar-2020) | 2.6b |
EV | 52.7b |
Biogen's current market capitalization is $48.9 b.
Annual
Quarterly
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 2.8b | 3.1b | 3.1b | 3.1b | 3.4b | 3.4b | 3.5b | 3.6b | 3.6b | 3.5b |
Cost of goods sold | 384.6m | 366.2m | 370.0m | 446.0m | 421.0m | 460.8m | 602.0m | 476.3m | 430.0m | 454.3m |
Gross profit | 2.4b | 2.7b | 2.7b | 2.7b | 2.9b | 3.0b | 2.9b | 3.1b | 3.2b | 3.1b |
Gross profit Margin, % | 86% | 88% | 88% | 86% | 87% | 87% | 83% | 87% | 88% | 87% |
Annual
Quarterly
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|
Cash | 924.0m | 1.2b | 1.5b | 4.1b | 1.3b | 2.4b | 2.2b | 1.7b | 2.3b | 2.6b |
Accounts Receivable | 1.5b | 1.6b | 1.6b | 1.9b | 2.0b | 2.0b | 2.1b | 2.0b | 1.9b | 2.1b |
Inventories | 921.6m | 936.5m | 1.0b | 890.8m | 931.7m | 916.6m | 770.2m | 776.7m | 751.8m | 858.8m |
Current Assets | 6.9b | 7.1b | 7.6b | 10.2b | 7.4b | 8.7b | 8.9b | 7.9b | 8.4b | 8.0b |
Annual
Quarterly
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 747.5m | 1.6b | 2.8b | 1.2b | 2.1b | 3.5b | 1.4b | 2.9b | 4.4b | 1.4b |
Depreciation and Amortization | 512.0m | 814.6m | 992.0m | 168.9m | 340.4m | 686.9m | 121.1m | 238.1m | 567.6m | 119.9m |
Inventories | (46.2m) | (85.3m) | (170.3m) | (2.6m) | (40.1m) | (31.9m) | (129.0m) | (108.7m) | (47.3m) | (62.2m) |
Cash From Operating Activities | 235.2m | 1.4b | 3.0b | 1.5b | 2.6b | 4.3b | 1.5b | 3.4b | 5.1b | 1.5b |
| USD | Y, 2020 |
|---|---|
EV/EBIT | 28.9 x |
EV/CFO | 35.9 x |
Financial Leverage | 2.1 x |
Biogen Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Nightstar Therapeutics | March 04, 2019 | $800 m |
| AliveGen | July 25, 2018 | $27.50 m |
| Karyopharm Therapeutics | January 25, 2018 | $10 m |
| Remedy Pharmaceuticals | May 18, 2017 | $120 m |
| Convergence Pharmaceuticals | February 14, 2014 | $675 m |
| Stromedix | February 14, 2014 | $75 m |
| Tysabri | February 28, 2013 | |
| Syntonix Pharmaceuticals | January 04, 2007 | $120 m |
| Fumapharm | May 31, 2006 | |
| Conforma Therapeutics | May 03, 2006 | $150 m |
Biogen Revenue Breakdown
Biogen revenue breakdown by business segment: 15.9% from Anti-CD20 Therapeutic Programs, 79.1% from Product Revenues and 4.9% from Other
Biogen Online and Social Media Presence
32.01k Twitter followers
Biogen has 32.01k Twitter Followers. The number of followers has increased 4% month over month and increased 10.5% quarter over quarter
Biogen's Trends
Twitter Engagement Stats for @biogen
4.5k
Tweets
254
Following
32k
Followers
72
Tweets last 30 days
34.4
Avg. likes per Tweet
95.8%
Tweets with engagement
Biogen Company Culture
Overall Culture
B
72/100
CEO Rating
C-
65/100
Compensation
A+
84/100
Diversity
A
81/100
Biogen News and Updates
June 04, 2020
Biogen Presents Positive Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020
CAMBRIDGE, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Today, Biogen Inc. (Nasdaq: BIIB) shared positive data from the 16-week cutaneous lupus erythematosus (CLE) portion of the Phase 2 LILAC study. The study evaluated the efficacy and safety of BIIB059, a fully humanized IgG1 monoclonal antibody (mA…
May 28, 2020
Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science
CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) is bringing its well-recognized Community Lab science learning program together with the Lemelson-MIT Program (LMIT) at the Massachusetts Institute of Technology to launch the new online Biogen-MIT Biotech in Action: Vir…
April 13, 2020
NYT: Biogen event led to 'superspreading' of COVID-19 among employees and their contacts
Shares of Biogen Inc. were down 0.3% in premarket trading on Monday after The New York Times reported on Sunday that a company event in late February led to "superspreading" of COVID-19 among its employees. Even after reports of positive tests among employees who attended the meeting came in, at le…
March 16, 2020
Thinking about trading options or stock in Biogen, Clorox, Centene, Netflix, or Walmart?
NEW YORK, March 16, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIIB, CLX, CNC, NFLX, and WMT. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...
March 12, 2020
Vir's stock gains 15% as it announces COVID-19 collaboration with Biogen
Shares of Vir Biotechnology Inc. gained 15% in premarket trading on Thursday after it said it intends to partner with Biogen Inc. to help develop and manufacture its monoclonal antibodies as a potential treatment of COVID-19. Biogen will handle clinical manufacturing of Vir's antibodies, the compa…
March 08, 2020
Biogen orders all workers to work from home after employees at management meeting test positive for coronavirus
Biogen Inc. has ordered all of its workers to work from home until further notice, as part of a sweeping round of measures implemented after employees who attended a Boston management meeting tested positive for the coronavirus that causes COVID-19. Biogen had about 7,400 employees worldwide as of …
Biogen Blogs
April 08, 2020
Biogen to Report First Quarter 2020 Financial Results April 22, 2020
Cambridge, Mass.— Biogen Inc. (Nasdaq:BIIB) today announced it will report first quarter 2020 financial results Wednesday, April 22, 2020, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET.
April 02, 2020
Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study
DEVOTE will evaluate the safety and potential for even greater efficacy of a higher dose of SPINRAZA in the treatment of spinal muscular atrophy (SMA) Well-established safety profile and proven efficacy of SPINRAZA in a broad range of patients supports exploration of the higher dose Biogen
March 30, 2020
Biogen to Webcast Encore Aducanumab Presentation From Virtual AAT-AD/PD Meeting on April 2, 2020
Cambridge, Mass. – March 30, 2020 – Biogen (Nasdaq: BIIB) today announced it will host a webcast of its encore presentation related to its Alzheimer’s disease investigational therapy, aducanumab, at the upcoming virtual AAT-AD/PDTM focus meeting. The data in this presentation were previously
March 18, 2020
Biogen Statement: Business Update Regarding COVID-19
The current COVID-19 pandemic has presented a substantial public health and economic challenge around the world. As governments, businesses and other organizations take unprecedented measures to help mitigate the spread of the outbreak, we want to reinforce our deep commitment to our employees, our
March 16, 2020
Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World
Most of the funds will be directed to support the global response and the immediate needs of communities hardest hit by COVID-19 CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Biogen Inc . (Nasdaq: BIIB) today announced that the Biogen Foundation has committed $10 million to support global
February 27, 2020
Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases
Broad collaboration for gene regulation therapies in neurology, initially focused on development of ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, and a neuromuscular target, with exclusive rights for nine additional undisclosed
Biogen Frequently Asked Questions
When was Biogen founded?
Biogen was founded in 1978.
Who are Biogen key executives?
Biogen's key executives are Michel Vounatsos, Stelios Papadopoulos and Susan Alexander.
How many employees does Biogen have?
Biogen has 7,400 employees.
What is Biogen revenue?
Latest Biogen annual revenue is $14.4 b.
What is Biogen revenue per employee?
Latest Biogen revenue per employee is $1.9 m.
Who are Biogen competitors?
Competitors of Biogen include Bayer, Amgen and Gilead Sciences.
Where is Biogen headquarters?
Biogen headquarters is located at 225 Binney St, Cambridge.
Where are Biogen offices?
Biogen has offices in Cambridge, Morrisville, Waltham, Washington and in 35 other locations.
How many offices does Biogen have?
Biogen has 39 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies